Antibody

15개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved15 programs
AntibodyLimited DatastaleAstraZenecaPhase 2

durvalumab + tremelimumab (STRIDE, STRIDE (durvalumab + tremelimumab))

Advanced Unresectable Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 185Status Recruiting
AntibodyLimited DatastaleAmgenPhase 3

Panitumumab (Panitumumab)

Colorectal Cancer; Resectable Colorectal Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#Popular#monoclonal-antibody+4
Trials 127Status Recruiting
AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab and Bevacizumab)

Hepatocellular Carcinoma · Resectable Hepatocellular Carcinoma

#ResectableHepatocellularCarcinom#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 58Status Discontinued
AntibodyLimited DatastaleGruppo Oncologico del Nord-OvestPhase 2

Balstilimab (Balstilimab)

Colorectal Cancer; Resectable Colorectal Carcinoma · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#monoclonal-antibody#ResectableColorectalCarcinoma+1
Trials 45Status Recruiting
AntibodyLimited DatastaleGruppo Oncologico del Nord-OvestPhase 2

Botensilimab (Botensilimab)

Colorectal Cancer; Resectable Colorectal Carcinoma · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#monoclonal-antibody#ResectableColorectalCarcinoma+1
Trials 38Status Recruiting
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf)

Advanced Unresectable or Metastatic Solid Malignancy · Advanced Unresectable or Metastatic Soli

#AdvancedUnresectableorMetastatic#Antibody#Phase2#monoclonal-antibody#Roche
Trials 15Status Active
AntibodyLimited DatastaleThe First Affiliated Hospital o…Phase 2

Adebellizumab (Adebellizumab)

Resectable Lung Non-Small Cell Carcinoma · Resectable Lung Non-Small Cell Carcinoma

#ResectableLungNon-SmallCellCarci#Antibody#Phase2#monoclonal-antibody#The
Trials 3Status Recruiting
AntibodyLimited DatastaleIovance Biotherapeutics, Inc.Phase 3

pembrolizumab (Keytruda, Lifileucel plus Pembrolizumab)

Metastatic Melanoma; Unresectable Melanoma · Metastatic Melanoma

#MetastaticMelanoma#Antibody#Phase3#monoclonal-antibody#UnresectableMelanoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 1

TACE combined with sintilimab and bevacizumab (TACE combined with sintilimab and bevacizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Phase1#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleSecond Affiliated Hospital of G…Phase 2

TACE combined with sorafenib and tislelizumab (TACE combined with sorafenib and tislelizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Phase2#monoclonal-antibody#Second
Trials 1Status Active
AntibodyLimited DatastaleWest China HospitalPhase 2

Tagitanlimab (Tagitanlimab)

Resectable Head and Neck Squamous Cell Carcinoma · Resectable Head and Neck Squamous Cell C

#ResectableHeadandNeckSquamousCel#Antibody#Phase2#monoclonal-antibody#West
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab+cetuximab (Toripalimab+cetuximab)

Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma · Patients With Locally Recurrent Resectab

#PatientsWithLocallyRecurrentRese#Antibody#Phase2#monoclonal-antibody#Junshi
Trials 1Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 2

MEDI4736 (Tremelimumab Plus Durvalumab, Tremelimumab Plus Durvalumab (MEDI4736))

Hepatocellular Carcinoma (HCC); Unresectable Hepatocellular Carcinoma · Hepatocellular Carcinoma (HCC)

#HepatocellularCarcinomaHCC#Antibody#Phase2#monoclonal-antibody#UnresectableHepatocellularCarcin+1
Trials 1Status Recruiting
AntibodyLimited DatastaleTongji HospitalPreclinical

apatinib plus camrelizumab (apatinib plus camrelizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Preclinical#monoclonal-antibody#Tongji
Trials 1Status Recruiting
AntibodyLimited DatastaleEli LillyPhase 2

ixabepilone + cetuximab (ixabepilone + cetuximab)

Triple Negative Locally Advanced Non-resectable Breast Cancer; Metastatic Breast Cancer · Triple Negative Locally Advanced Non-res

#TripleNegativeLocallyAdvancedNon#Antibody#Phase2#monoclonal-antibody#MetastaticBreastCancer+1
Trials 1Status Active